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Ventricular Assist Devices (VADs) have demonstrated their therapeutic role in cardiac 
rehabilitation. However, due to the complexities of caring for these patients and the relatively 
limited clinical experience, identifying candidates for weaning remains challenging. This study 
proposes the use of a Clinical Decision Support System (CDSS) to both aid in the identification 
of VAD weaning candidates, and as a tool for predicting patient outcome.  
Based upon the UPMC VAD weaning experience, three CDSS models were developed:  an 
expert model, a data model, and an expert/data hybrid model. The decision structures of the 
expert model were elicited from an 11 member, multi-disciplinary panel through a series of 
structured interviews and polls. Pattern recognition through Artificial Neural Networks and 
Natural Language Processing was used to analyze patient data and acquire the decision structures 
for the data model; all patients receiving a Thoratec VAD which were considered for weaning 
between 1996 and 2004 (n=19), regardless of outcome, were included in this study. Decision 
structures were modeled using Bayesian Belief Networks and their predictive values were 
assessed. A user interface, based on a pocket-PC, was developed to anticipate the translation of 
this system to clinical practice.  
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The hybrid model, consisting of a 21-parameter health screening and a 3-tier evaluation of 
cardiac recovery, was the best predictor of outcome, predicting 90% true weans, 100% true 
transplants, 0% false weans and 10% false transplants. By objectively combing knowledge from 
experts and data, this study illustrates how a CDSS can facilitate the decision making processes 
for identifying VAD weaning candidates and promote responsible and widespread use of VADs 
for cardiac rehabilitation. 
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1.0 INTRODUCTION 
 
 
 
There is mounting evidence to suggest that the use of Ventricular Assist Devices (VADs) for the 
treatment of end-stage congestive heart failure can lead to myocardial recovery. In addition to 
providing circulatory support, studies report that by unloading the native ventricle with a VAD, 
the myocardium “reverse remodels” and indices of cardiac function improve [1-11]. 
Furthermore, several medical centers have reported the experience of recovery in patients who 
were supported while awaiting heart transplants [12-25]. In these cases, patients were weaned 
from VAD support and the devices were explanted, thus allowing the patients to forego a 
transplant altogether.   
Despite the promising evidence for the use of VADs as a mechanism for recovery, the 
incidence of VAD weaning remains low [26, 27]. Due to the complexities of caring for these 
patients and the relatively limited clinical experience, identification of VAD weaning candidates 
presents a significant challenge.   
Identifying these candidates requires that the clinicians, who make a decision regarding the 
patient’s condition, do so under a large degree of uncertainty. Moreover, they must speculate as 
to the patients’ benefit from weaning (versus a transplant) and find a way to combine the 
opinions of the entire clinical team. The manner in which clinicians face these challenges 
requires objectivity and time to assess all alternatives— a major difficulty in an atmosphere 
where decisions must be made quickly.  
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This study proposes the use of a Clinical Decision Support System as an aid in overcoming 
these challenges. By integrating expert- and data-derived knowledge into a portable, computer-
based decision model, this study illustrates how such a system may aid in the identification and 
evaluation of VAD weaning candidates. 
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2.0 BACKGROUND 
 
 
 
2.1  HEART FAILURE 
 
 
The American Heart Association reports that in the United States alone, heart failure affects 
4,900,000 people and associated costs amount to $27.9 billion each year. With 550,000 new 
cases diagnosed annually, congestive heart failure (CHF) has become a national epidemic, 
causing and contributing to approximately 300,000 deaths per year [28].  
CHF can be defined as the inability of the heart to pump enough blood to sustain normal 
bodily functions. Risk factors include smoking, high cholesterol, diabetes, drug and alcohol 
abuse, and obesity. Causes include coronary artery disease, hypertension, metabolic disorder, 
infection, toxin exposure, valvular heart disease, and severe anemia [29, 30].  
Signs and symptoms of heart failure include a decrease in cardiac output, an increase in 
ventricular filling pressures, and exercise intolerance. In response to these conditions, the body 
attempts to maintain homeostasis by augmenting blood volume via salt and water retention, 
maintaining pressure for perfusion of the vital organs via vasoconstriction, and increasing heart 
rate and ejection via sympathetic stimulation. In the long-term, this physiological response only 
exacerbates the condition. By retaining salt and water, the kidneys are adversely affected and the 
pulmonary and systemic venous systems become congested. Vasoconstriction and sympathetic 
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stimulation increase the energy expenditure of the heart which can lead to a dilated heart with 
impaired contractility. The pathogenesis of heart failure is detailed in Figure 1 below [31].   
 
 
 
 
 
 
Figure 1: Pathogenesis of Congestive Heart Failure 
 
 
2.1.1 Treatment Options 
 
 
Treatment of CHF depends upon the severity of the condition.  As shown in Figure 2, treatment 
modalities include lifestyle changes, pharmacotherapy, surgical intervention and mechanical 
circulatory assist. 
 4
  
Figure 2: Treatment options for Congestive Heart Failure 
 
Lifestyle changes are non-surgical, non-pharmacological treatments that are useful in less 
severe cases of heart failure. In this type of treatment, the clinician may advise the patient to 
exercise and eliminate certain foods from their diet. In addition, the patient should be educated 
regarding their disease and psychological intervention may be suggested. If the patient does not 
respond to these changes, pharmacotherapy may be added to their treatment.  
There are several types of pharmacotherapy used to treat CHF: Diuretics, ACE Inhibitors, 
Beta Blockers, Inotropes, and Antirrhythmics. Diuretics assist in decreasing blood volume, or 
preload, by increasing the secretion of salt and water. ACE (Angiotensin Converting Enzyme) 
Inhibitors regulate the vasoconstrictive, and salt retentive actions of angiotensin. Beta Blockers 
decrease afterload, heart rate and renin release. Inotropes increase contractility to improve 
cardiac output. Antirrhythmics reduce the frequency and/or severity of arrhythmias. If the patient 
does not respond to pharmacotherapy, more aggressive treatment is often warranted.  
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Some minimally invasive procedures exist, which include angioplasty, coronary stents, and 
implanted pacemakers or defibrillators. However, more invasive surgical treatment is usually 
needed for severe heart failure patients. This may include coronary artery bypass surgery, valve 
repair/replacement, and ventricular remodeling. Patients who do not respond to these surgical 
interventions will typically require a heart transplant.  
Heart transplants have been performed since 1967 and for patients with end-stage heart 
failure, transplantation offers the chance to extend life or improve the quality of remaining life; 
71% of heart transplant recipients survive five years after transplant and, on average, the 
transplant will extend the patient’s life by 9 years [28, 32, 33]. However transplantation is not 
without its problems. For example, to prevent rejection of the heart, the patient must receive 
chronic immunosuppressive therapy [34]. This therapy not only compromises the patient to 
infection,  it also severely affects their quality of life [35].  As the demand for donor organs far 
exceeds the supply, approximately 70% of these patients are placed on a form of life support, 
including mechanical circulatory assist devices, while waiting for a transplant [32].  
 
 
 
2.2 VENTRICULAR ASSIST DEVICES 
 
 
In the United States, the use of mechanical circulatory assist devices has been increasing to 
accommodate those for whom a transplant is unavailable in a timely fashion, and also for those 
who are ineligible for transplant [36-38]. 
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One of the widely used mechanical circulatory assist devices is the Ventricular Assist Device 
(VAD). This device restores blood flow, unloads the native ventricle and can support either the 
systemic circulation through the left ventricle, the pulmonary circulation through the right 
ventricle, or both.  
VADs restore flow through either an electromechanically, pneumatically, magnetically, or 
hydraulically driven pump. These pumps can be classified as displacement pumps, which 
produce pulsatile flow, or rotary pumps, which produce continuous flow. The VAD is placed 
either extra- or intra-corporeally and the pump is powered by an implanted or external power 
source. Blood enters the pump though a cannula connected to the ventricle and is ejected into the 
body's arterial system through an outflow cannula. The VAD is monitored by an electronic 
controller that can respond to the recipient’s changing heartbeat and circulatory demands. A 
collection of various VADs is shown in Figure 3.  
Although VADs are most often used to support the circulation of patients awaiting a donor 
heart, they are also used as temporary support for patients whose native heart is recoverable, and 
as permanent support for patients ineligible for transplant.  
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Figure 3: Ventricular Assist Devices 
 
 
2.2.1 Bridge to Transplant 
 
 
In 1969, Cooley et al were the first to use a VAD for supporting a patient awaiting 
transplantation [39]. This strategy of VAD therapy has since been termed “Bridge to Transplant” 
(BTT). In this case, there is no expectation for recovery of the heart, rather, the purpose of VAD 
support is to maintain blood flow and end organ function until a transplant becomes available.  
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In the United States, approximately 15% of transplant candidates require a VAD as a BTT 
[40]. The Food and Drug Administration (FDA) has approved the following four pulsatile VADs 
for use as a BTT: Thoratec, HeartMate 1000 IP, HeartMate VE, and Novacor.  
When compared to patients managed by medical therapy alone, the use of VADs as a BTT 
has been shown to improve both clinical and quality of life outcomes and even lower expenses 
[20, 41-45]. This technology has made it possible for patients to be discharged from the hospital 
and await a donor heart from home. Furthermore, at least 67% of these patients survive to 
receive a donor heart and one-year post-transplant survival is 80%-- these results equal or exceed 
the survival rate in patients who undergo transplant alone [46, 47].  
 
 
2.2.2 Destination Therapy 
 
 
In cases where CHF patients are ineligible for transplant, VADs can be used to provide 
permanent circulatory support. This strategy of VAD therapy has been termed “Destination 
Therapy” (DT).  As a result of the landmark REMATCH (Randomized Evaluation of Mechanical 
Assistance Therapy as an Alternative in Congestive Heart Failure) study, the FDA recently 
approved the HeartMate LVAD for DT.  In the REMATCH study, it was concluded that even if 
no chance of transplant exists, long-term use of an LVAD can significantly improve survival 
rates and quality of life [48]. Although promising, DT is associated with only modest long-term 
device reliability and high costs. 
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2.2.3 Bridge to Recovery 
 
 
“The heart, like any other diseased organ, improves with rest.”  
-George Burch, 1966 [49]  
In some cases, VADs are used to temporarily support patients while the native heart recovers. 
After the heart has recovered its function, patients can be weaned from support and the device 
can be removed. This strategy of VAD therapy has been termed “Bridge to Recovery” (BTR). 
Currently, the FDA has only approved BTR for post-cardiotomy cardiogenic shock patients—
patients who cannot be weaned from a cardiopulmonary bypass machine following open heart 
surgery. However, several medical centers have reported instances in which BTT patients have 
recovered function of their heart while waiting for a transplant; many of these patients were able 
to be weaned from VAD support and remain device/transplant free [12-25]. Recovery in BTT 
patients is a promising option; the patient is able to forego a transplant altogether, thereby 
avoiding the long-term complications associated with transplantation and opening up the 
availability of the organ for another patient on the waiting list.  
 Due to the large number of patients who could potentially benefit from BTR, in recent years, 
research efforts have been geared towards understanding the mechanisms behind VAD-induced 
myocardial recovery and learning from the collected clinical experience with weaning. 
 
 
2.2.3.1 Myocardial Recovery.     Improvement in indices of cardiac function as well as  
biological and histological remodeling of the myocardium of VAD recipients has been reported 
in numerous studies. The reversibility of CHF at the functional, structural, cellular, and 
molecular levels has been termed “reverse remodeling”  [11]. 
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A Columbia Presbyterian case study published in 1996 reported that at the time of intended 
transplantation, a VAD patient's native heart had returned to a normal geometry, had a normal 
ejection fraction, and was able to maintain normal pressures and flows [1]. Similarly, several 
other centers have reported an improvement in ejection fraction, increased exercise capacity and 
normalization of heart geometry [2-5].  
Biological and histological evidence for cardiac recovery has been demonstrated through a 
comparative analysis of paired myocardial samples harvested at the time of VAD implantation 
and explantation. The Texas Heart Institute conducted a retrospective study comparing selected 
anatomic, physiologic, hemodynamic, histological, and biochemical parameters of the left 
ventricle before and after VAD support.  Based on these parameters, they found that ventricular 
function did improve in patients after being supported by a VAD [19]. Several studies have also 
shown that unloading is associated with better myocyte function and the reversal of abnormal 
gene expressions; improved myocyte contractile properties and normalization of genes that 
regulate brain natriuretic peptide, calcium handling, tumor necrosis factor alpha and cytoskeleton 
proteins has been demonstrated [6-10].  
 
 
2.2.3.2 Clinical Experience with VAD Weaning.     In 1995, Nakatani et al were among 
the first to report on the recovery of the native ventricle in 4 BTT patients [21]. They were able 
to successfully wean 2 patients and since then, a limited number of other medical centers have 
reported experience with weaning BTT patients.  
In 1999, the Texas Heart Institute reported weaning in 5 BTT patients [18]. Of these, one 
patient died of noncardiac-related causes and, at the time of publication, the remaining 4 patients 
were alive and well 2, 14, 33, and 35 months after VAD removal. They studied routine 
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echocardiographic and right heart catheterization measurements as indicators of recovery; a 
significant increase in cardiac output and ventricular ejection fraction were noted in the weaned 
patients.  
In 2001, the Berlin Heart Center reported VAD weaning of 28 BTT patients [13]. Of those, 4 
died, 8 eventually underwent transplant, and 16 showed stable recovery with follow-up times 
ranging from 1 month to 5.5 years. They used echocardiographic measures of ventricular 
ejection fraction and end-diastolic diameter made with the VAD turned off for 4 minutes as a 
guide to functional recovery.   
Columbia Presbyterian has reported VAD weaning in 3 BTT patients [24, 25]. They studied a 
combination of echocardiography, right heart catheterization, exercise testing and serial 
endomyocardial biopsies for recovery of myocardial function. These studies introduced the value 
of exercise hemodynamics and metabolic studies in identifying patients with functional recovery.  
In 2004, Toronto General Hospital published a case study of a BTT patient who was 
successfully weaned [12]. To assess recovery, they studied both echocardiographic measures and 
exercise performance. Echocardiographic measures, with simultaneous right heart 
catheterization, were performed every 10 minutes at VAD rates of 40, 30, and 20 cycles/min, and 
finally with the device off. Exercise testing was performed to exhaustion while respiratory gases 
and heart rate were monitored continuously.  
The University of Pittsburgh Medical Center (UPMC), who currently holds the largest 
single-center experience with VAD weaning in the United States, has reported successful 
weaning in 10 BTT patients [14-16]. Of these, all survived to hospital discharge, 2 eventually 
underwent cardiac transplant, and 8 remain alive and well with follow-up times ranging from 1.5 
to 5 years. Non-invasive echocardiographic and exercise study measurements were used to 
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assess recovery. Gorcsan et al have shown that these measurements can clearly define the 
population of patients that can be removed from VADs from those who will remain VAD 
dependent [14]. In a study of 19 BTT patients who were studied for possible recovery, Gorcsan 
was able to show that the patients who were eventually weaned demonstrated greater measures 
of cardiac function, such as ventricular power and peak oxygen consumption, as shown in Figure 
4. 
 
 
 
 
 
 
Figure 4:  Echocardiographic and exercise data from recovery studies performed at UPMC 
 
Listed in Table 1 are the cardiac recovery protocols used by the medical centers mentioned 
above. In summary, the protocols vary, but all include an echocardiographic assessment of the 
heart and may include additional assessments such as exercise and right heart catheterization 
tests.  
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Table 1: Protocols for assessing cardiac recovery 
 
 
 
 
 
 
2.2.3.3 Challenges facing VAD weaning.     Despite the mounting evidence to suggest that 
VAD patients can experience direct cardiac benefits from mechanical unloading of the ventricle, 
the incidence of VAD weaning remains relatively low [26, 27].   Although studies of myocardial 
function in VAD patients suggest that the native heart can mend itself after CHF and that VAD 
support appears to play a large role in the recovery process, the clinical significance of these 
findings must be better understood; it remains unclear why some patients exhibit recovery while 
others do not and if myocardial recovery can be sustained in the long-term. Furthermore, from 
the limited clinical experience with VAD weaning, it is evident that few centers regularly screen 
for recovery and protocols for assessing recovery vary across the board—indicating a lack of 
consensus regarding markers (or predictors) of recovery [13]. Although some centers claim to 
have found reliable markers of recovery, it is important to realize that, due to selection bias, 
these markers may not be applicable at other centers. Most reports of VAD weaning note that 
only a certain subset of patients were evaluated for recovery. While the subsets were most likely 
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not chosen randomly, the methods for choosing these groups were not published in any of the 
studies cited. Therefore, in order to fully understand the trends that govern the recovery of the 
patients at each center, the subset selection process must also be studied.   
Methods for identifying potential candidates for recovery and development of weaning 
protocol are clearly in their infancy. While the limited clinical experience can be in part 
attributed to the lack of FDA approval for VAD use as a BTR (in non post-cardiotomy patients), 
the disparity between the number of patients that have been successfully weaned versus the 
number of patients evidencing myocardial recovery implies the need for a more systematic, 
quantitative approach. This study proposes the use of a Decision Support System for identifying 
and assessing VAD weaning candidates; the rationale for using this system is detailed in the 
Study Design section of this thesis. 
 
 
 
2.3 DECISION SUPPORT SYSTEMS 
 
 
Decision Support Systems (DSS) apply the principles of decision theory, probability theory, and 
decision analysis in an interactive computer-based tool to help decision makers answer 
questions, solve problems, and support or refute conclusions [50-53]. In Making Hard Decisions, 
Clemen and Reilly write that DSS provide the structure and guidance needed for thinking about 
hard decisions, which in turn allows people to make more effective decisions on a more 
consistent basis [54].  The main advantages of using these systems lie in their ability to integrate 
knowledge from multiple sources and minimize the biases of decision makers.  When used 
properly, DSS have been shown to increase objectivity, productivity, efficiency and effectiveness 
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in decision making, in essence, enhancing human judgment— especially in complex and/or high-
stress situations [51]. 
It should be emphasized that DSS, unlike so-called “Expert Systems,” are designed to aid the 
decision maker, not replace him or her. In response to criticism regarding the role of DSS, Derek 
Bunn writes, “The basic presumption of decision analysis is not at all to replace the decision 
maker’s intuition, relieve him or her of the obligations in facing the problem or to be, worst of 
all, a competitor to the decision maker’s personal style of analysis but to complement, augment 
and generally work alongside the decision maker [55].”  
DSS are built upon a knowledge base derived from human experts and/or data. The system is 
designed such that when the user requests assistance with a decision, the knowledge base can be 
tapped using an inference engine and an analysis of the decision can be made based directly upon 
the expert- and/or data- derived knowledge. Since the methods used for this analysis are highly 
reliable and can be performed relatively quickly, DSS have continued to gain popularity in fast-
paced, high-stakes domains such as the military, and in the fields of business, engineering, and 
medicine. 
 
 
2.3.1 Clinical Decision Support Systems 
 
 
Since the late 1950’s, there has been a growing interest in the use of computers as an aid in 
medical decision making [52]. Cooper writes “A major driving force [behind this interest was] 
the realization that the quantity of clinically relevant medical knowledge [was becoming] too 
great for one person to remember. [56]” Given the exponential growth of scientific literature and 
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specialty conferences, keeping current with the latest medical knowledge has become an even 
greater challenge, making the aid of computers more relevant than ever before.   
Several Clinical Decision Support Systems (CDSS) have emerged as a result of this interest. 
A collection of current CDSS are shown in Table 2. These systems have been designed for use in 
various specialties of medicine including oncology, anesthesiology, cardiology, gynecology, and 
gastroenterology; from aiding clinicians in the decisions associated with anemia to those 
associated with ventilator control, applications are widespread [57-72]. Although a majority of 
CDSS are used for patient diagnosis, a number are also used in planning medication and therapy, 
and in routine patient evaluation [73]. 
 
 
 
Table 2: Clinical Decision Support Systems 
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Many CDSS are used in critical care patient areas, such as the emergency room and intensive 
care unit, where decisions must be made quickly [62-65].  These systems are also quite useful in 
situations where physician expertise is constantly needed for optimal patient care, as in pain 
management [59].  
 
2.3.1.1 Applications in Cardiology.     In recent years, a large number of CDSS have been 
designed specifically for use in cardiac diagnosis, management, and evaluation; the increasing 
number indicates a distinct struggle over decision making in this medical specialty [66-69, 71, 
72, 74-80].  
Antonnson et al reported the development of a CDSS for supporting the decisions of 
surgeons before, during, and after implantation of certain circulatory support devices, including 
the intra-aortic balloon pump [66]. Their system uses a combination of rule- and case-based 
reasoning to provide predictions to the surgeon regarding the type of device that the patient 
ought to receive and the associated surgical procedures that should be used.  
A team of computer scientists and clinicians at the Massachusetts Institute of Technology 
have been continuously developing a CDSS over the last decade for assisting in the differential 
diagnosis of cardiovascular disorders [69, 79, 80]. Comparing diagnoses made by the system to 
those made by physicians in a retrospective analysis of 600 patients cases, the system has a 
higher sensitivity (53.0% vs. 34.8%) and significantly higher comprehensiveness (57.2% vs. 
39.5%).  
A group at the Mayo Clinic has successfully used a CDSS to manage patients with resistant 
hypertension [68]. The system used serial hemodynamic measurements and a predefined 
treatment algorithm to select medication. A group of physicians were then asked to consult the 
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CDSS when managing their patients. In a 3-month clinical trial, the patients managed by the 
system demonstrated superior control over blood pressure than those managed by clinical 
judgment alone.  
Several commercial CDSS are available for cardiac diagnosis and monitoring and are 
currently used at medical centers across the nation [72]. The Agilent Acute Cardiac Ischemia 
Time-Insensitive Predictive Instrument (Agilent Technologies; Andover, MA) provides real-time 
guidance in the diagnosis of acute cardiac ischemia and improves the accuracy of triage 
decisions. CardioSys Exercise Testing System (GE Marquette) monitors and analyzes data from 
a patient undergoing exercise testing procedures. DynaPulse by Pulse Metric (San Diego) and 
Omron by Omron Healthcare Inc. (Vernon Hills, IL) are ambulatory blood-pressure monitors 
that use pattern recognition and fuzzy-logic algorithms to increase measurement accuracy.  
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3.0 STUDY DESIGN 
 
 
 
3.1  RATIONALE 
 
 
A challenging decision problem can be defined as one which is significantly complex enough to 
strain the limits of intuitive judgment [81]. As defined by Clemen and Reilly, a challenging 
decision involves at least two of the following four sources of difficulty [54]: 
1. Complexity 
a. Keeping all issues in mind at one time is nearly impossible 
2. Uncertainty 
a. Unknown values for variables involved in the decision 
3. Multiple Objectives 
a. Progress in one direction may impede the progress in others 
4. Different Perspectives 
a. Different individuals may disagree on the uncertainty of various outcomes 
In the particular case of identifying and assessing VAD weaning candidates, the clinicians 
who make a decision regarding the patient’s status must do so under a large amount of 
uncertainty, with multiple objectives in mind, while factoring in a number of different 
perspectives-- a challenging decision problem indeed.  
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While the care of VAD patients is complex by nature, the decision to wean the patient 
demonstrates an even greater degree of complexity. The limited clinical experience with VAD 
weaning, coupled with the lack of consensus regarding markers of recovery contribute to the 
large amount of uncertainty faced by clinicians. Furthermore, the clinicians are forced to 
speculate as to the patient’s benefit from weaning versus a transplant, a risky assessment in light 
of the limited data; while it is well known that transplants can extend the life of CHF patients by, 
on average, 9 years, the longest follow-up data reported for a weaned patient is 5.5 years. 
Although the objective in all cases is to optimize the patient’s quality of life and survival, a 
course of treatment directed towards optimal transplantation has different characteristics than 
one that is directed towards recovery. Finally, combining different perspectives not only involves 
combining input from the multiple disciplines involved in the patient’s care, it also involves 
learning from past cases, and keeping current with the exploding amount of scientific literature 
related to VAD therapy.  
In practice, clinicians find ways to cope with the uncertainty, the outcomes that extend over 
several time periods, the opinions from multiple individuals, and the often conflicting objectives. 
However, these coping mechanisms are often inefficient, highly subjective, and narrowly 
focused-- leading to non-optimal decision making which ultimately impedes progress. 
In order to successfully address these difficulties, the decision maker requires a thorough 
understanding of the problem and careful thought regarding the important issues [54].  This 
requires time—a scarce resource in an environment where decisions need to be made quickly. 
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A DSS is an ideal solution for overcoming these difficulties. Through decision analysis, it is 
possible to organize complex problems into structures that can be more easily understood and 
analyzed, identify sources of uncertainty and represent that uncertainty in a systematic and useful 
manner, and address multiple objectives and different perspectives in an impartial, evidence-
based manner [54]. 
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3.2 OBJECTIVE AND SPECIFIC AIMS 
 
 
This study proposes the use of a Clinical Decision Support System (CDSS) for both aiding in the 
identification of VAD weaning candidates and as a tool for predicting patient outcome. The 
objective of this study was to develop a CDSS that could mimic the decision-making processes 
used at UPMC when identifying VAD weaning candidates.  
Toward this objective, knowledge was elicited from both experts and patient data. Three 
different decision models were developed and each was assessed for its predictive value.  
Specifically, the aims of this study were to: 
1. Develop and evaluate a decision model for predicting patient outcome based upon expert-
derived knowledge. 
2. Develop and evaluate a decision model for predicting patient outcome based upon data-
derived knowledge. 
3. Construct and evaluate a hybrid expert/data decision model for predicting patient 
outcome. 
4. Design a graphical user interface for clinical implementation of the models.  
It was hypothesized that the third model, which combined both expert- and data- derived 
knowledge, would predict patient outcome with greater accuracy than by using each source of 
knowledge separately.  
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3.3 EXPERT PANEL 
 
 
The Artificial Heart Program (AHP) at UPMC is one of the top clinical programs of its kind in 
the world. Since 1985, UPMC researchers have been at the forefront of advances in VAD 
therapy, supporting nearly 300 patients for a period of time that amounts to more than 70 years 
[82]. Members of the AHP clinical team have received national recognition for their services, 
including prestigious awards, and are globally regarded as experts in this field [83-85].  
11 members of the AHP clinical team were asked to participate on the expert panel for this 
study. As shown in Figure 5, and detailed in Appendix A, the panel was composed of a diverse, 
multi-disciplinary group representing many aspects of the patient’s care including surgery, 
clinical bioengineering, nursing and psychiatry among others.   
 
 
 
 
 
 
Figure 5: Disciplines represented in the expert panel 
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3.4 PATIENT DATA 
 
 
In accordance with HIPAA (Health Insurance Portability and Accountability Act of 1996), de-
identified patient data was obtained from the UPMC VAD registry via an honest broker.  Patient 
cases considered for this study included patients on LVAD or BiVAD Thoratec devices who 
were BTT patients but considered for recovery at UPMC between 1996 and 2004. All patients 
had been assessed for recovery by the same clinical team and participated in echocardiographic 
and/or exercise weaning studies. Patient cases were included regardless of outcome or post-
explant status. 
Although a total of 161 VAD implants were performed between 1996 and 2004, the inclusion 
criteria described above resulted in a population of 19 patients (12%), of whom 10 were weaned, 
and 9 were transplanted. It should be noted that these were the same subjects considered in the 
Gorscan et al and Simon et al studies [14, 16].  
Overall, patients in this group received VAD support for at least 42 days and at most 282 
days, the mean age was 35 years old, 63% were female and 84% were Caucasian. Of the 9 
transplanted patients, 2 received an LVAD, 7 received a BiVAD, and 6 remain alive. Of the 10 
weaned patients, 5 received an LVAD, 5 received a BiVAD, and 8 remain alive and 
device/transplant free; the weaned group was composed of primarily female, non-ischemic 
patients (3 myocarditis, 4 post-partum cardiomyopathy, and 1 idiopathic cardiomyopathy). 
Outcome, device configuration, and post-explant status for each patient is shown in Table 3. 
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Table 3: Patient outcome, device configuration and post-explant status 
 
 
 
 
 
 
The seven data categories available for these patients included: demographics, complications, 
laboratory results, right heart catheterization results, exercise test results, echocardiography test 
results, and shift notes. While only 32% of the patients had complete data sets, 53% were 
missing only one category, and all remaining patients were missing at most two categories. Table 
4 details the data categories available for each patient. The variables in each of numerical data 
categories (a total of 250) are detailed in Appendix B and an excerpt from a shift notes file is 
included in Appendix C. 
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Table 4: Patient data categories and data completeness 
 
 
 
 
 27
 
 
 
 
 
4.0 METHODS 
 
 
 
First, knowledge was acquired from experts and patient data. Next, the structure and numerical 
parameters associated with this knowledge were used to build the decision models. Finally, a 
graphical user interface was designed for clinical implementation of the model.  
 
 
 
4.1 KNOWLEDGE ACQUISITION 
 
 
Knowledge was elicited directly from experts and patient data. In the case of experts, this was 
accomplished through interviews and questionnaires. In the case of patient data, knowledge was 
acquired through two data mining techniques: Artificial Neural Networks and Natural Language 
Processing.  
 
 
4.1.1 Expert-derived Knowledge 
 
 
Through a series of structured interviews and questionnaires, retrospective experience with 
weaning was acquired from the expert panel.  
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4.1.1.1 Interviews.     Interviewing is considered the classic method for acquiring knowledge 
from experts [67, 86, 87]. However, if performed in the traditional free form, interviews can be 
inefficient; as experts are normally busy individuals, maintaining efficiency in the knowledge 
acquisition process is a must for both parties. Therefore, “structured interviews,” or interviews in 
which a prop is used to guide the expert in divulging information are often employed when 
designing DSS [86]. The prop assists in maintaining focus of the interview; it can be anything 
from a patient chart to a film clip. 
In this study, experts were interviewed individually and in small groups 3 times over the 
course of 2 years. These interviews were informal and were conducted both in person and 
electronically. The goal of the interviews was to capture procedural knowledge related to VAD 
weaning.  
During the first interview, the expert was asked to describe the protocol he or she would use 
to determine if a patient could be weaned. After the interview, the resulting protocol was 
transformed into a binary decision flowchart and presented to the expert during a second 
interview. At that time, the expert was asked to review and revise the flowchart. Upon receiving 
an approved or revised flowchart from each expert, flowcharts from all experts were combined 
into one. In a third interview, the combined flowchart was presented to each expert and they 
were asked to review and revise the flowchart. Upon receiving the approved or revised 
flowcharts from each expert, the commonalities from all flowcharts were combined into one final 
decision flowchart.  
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4.1.1.2 Questionnaires.     After the final decision flowchart was constructed, experts were 
asked to take part in a questionnaire.  The goal of the questionnaires was to add a probabilistic 
dimension to the decision flowchart and capture expert treatment preferences and risk attitudes. 
Two 12-item questionnaires were completed in 2 sessions, and questions were asked in an 
informal, interview-style.  
Due to the binary nature of the final decision flowchart, weaning was only recommended if 
all variables were in their positive form. Therefore, experts were asked to consider less than ideal 
situations (a combination of variables in their positive and negative states) and estimate the 
percentage of patients who could be successfully weaned based upon those characteristics. To 
ensure consistency in the responses, questions were repeated in their reverse form. For example, 
if for 4/5 variables they answered 90%, then 1/5 variables should be 10%. If the probabilities did 
not directly complement each other, the experts were asked to reevaluate their estimates. A final 
8x6 matrix of probabilities was derived from averaging the probabilities elicited from all experts.  
 
 
4.1.2 Data-derived Knowledge 
 
 
According to Witten and Frank, data mining can be defined as the act of exploring and analyzing 
large amounts of data in order to detect meaningful rules, trends, insights and relationships [88].  
Often referred to as pattern recognition, data mining is performed semi-automatically through the 
use of specialized software. Through data mining, it is possible for the computer to produce 
models of historical data that can be used later for predictions of new cases; the technique for 
building these models is called machine learning [89].  
 30
 In this study, two data mining techniques were used to acquire knowledge and “learn” from 
the patient data: Artificial Neural Networks (ANN) and Natural Language Processing (NLP). 
ANN were used to analyze numerical data from the demographics, complications, labs, rh cath, 
echo, and exercise data. NLP was used to analyze the textual data found in the shift notes. The 
goal in using these data mining techniques was two-fold: to identify new patterns within the data 
and to confirm suspected relationships between variables.    
 
 
4.1.2.1 Artificial Neural Networks.     ANN are designed to function like the human 
nervous system and, similarly, their basic units are called neurons [67, 86]. As shown in Figure 
6, the neurons are organized into three layers: input layer (stimulus), hidden layer (processing of 
stimulus), and output layer (final response to stimulus). The neurons in each layer are linked in 
parallel through connections called synapses. The first layer, the input layer, is where the input 
data is presented for analysis. Values from the input layer are propagated from each neuron to 
every neuron in the next layer, the hidden layer, and the values are modified during transmission 
by randomly assigned weights. Using “error back propagation,” each input is multiplied by the 
assigned weight and propagated forward through the network to generate a prediction. The error 
in prediction is fed backwards through the network, modifying the weights by small amounts. 
This process is repeated for all inputs, many times, until the network has the lowest error in 
prediction. Eventually, a result is delivered in the third layer, the output layer. The result is a list 
of the inputs, ranked in order of importance, that best model the data that was presented in the 
first layer.  
Since the layer in which the complex processing takes place is hidden from the user, a 
common criticism of ANN is that it is difficult to understand the exact reasoning that goes into 
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the results; for this reason, ANN are sometimes referred to as “black boxes” [89].  However, the 
prediction accuracy of ANN is generally high and as such, they have gained widespread 
acceptance as a powerful data mining technique [67, 90, 91].  
 
 
 
 
 
 
 
Figure 6: Artificial Neural Network 
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In this study, ANN analysis was performed using SPSS Clementine 7.0 [92]. The goal was to 
narrow down the sets of variables that best correlated with weaning among the 250 variables 
available. As shown in Figures 7-9, a data mining scheme was first defined (Figure 7); the input 
data was presented and the target, in this case Patient Outcome, was identified (Figure 8), then, 
the settings for running the ANN were assigned (Figure 9). The ANN was set to run in “Prune” 
mode with overtraining prevented by using only 50% of the data set at a time. Prune mode 
allowed the network to remove surplus inputs when training and yield a minimized data set; 
although time consuming, this setting has been known to yield the best results [89, 93].  
 
 
 
 
 
 
 
Figure 7: Clementine data mining scheme 
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Figure 8: Defining inputs and target in Clementine 
 
 
 
 
 
 
Figure 9: Artificial Neural Network settings 
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Upon running the ANN, a graph, as shown in Figure 10, was displayed in which the error 
back propagation could be visualized. Since training data sets often takes long durations of time 
(usually over the course of a night), the graph was useful in tracking training progress. 
 
 
 
 
 
 
Figure 10: Artificial Neural Network real-time analysis 
 
Eventually, the minimized data set, with inputs ranked in order of importance to the target, was 
given as output, which is shown in Figure 11. As a final step, known outcomes were compared to 
those given by the ANN, as shown in Figure 12. Each numerical data category was analyzed 
using this methodology. 
 35
  
 
Figure 11: Artificial Neural Network output 
 
 
 
 
 
 
Figure 12: Artificial Neural Network output analysis 
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4.1.2.2 Natural Language Processing.     NLP, also known as text mining, is a subfield of 
Artificial Intelligence and Linguistics. It studies the problems inherent in the processing and 
manipulation of natural language, and, is devoted to making computers "understand" free text 
using predetermined rules and patterns of language [86].  
In this study, the main software used for NLP was Concordance 3.2 [94].  This software is 
able to take a text of any size and organize words by frequency and context [95]. The goal in 
processing the text was to detect speech patterns that may be associated with weaned patients. In 
preparation for NLP, the shift notes were filtered for common words and checked for spelling 
errors using a word processor.  The texts were then analyzed with Concordance one at a time; the 
output consisted of the words listed in order of frequency and context, as shown in Figure 13. 
Based upon the types of words in these documents, contextual categories were created.  The 
word frequency lists were exported into Excel and words were manually assigned to their 
respective category; words that did not fall into a category were omitted. Finally, the total 
frequencies of words in each category were compared between the weaned and transplanted 
patients.  
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Figure 13: Concordance output showing words organized by frequency and context 
 
  
  
4.2 DECISION MODELING 
 
 
Decision structures were formed using the knowledge acquired from experts and/or learned from 
the patient data were modeled using Bayesian Belief Networks (BBN).  
 
 
4.2.1 Bayesian Belief Networks 
 
 
Bayesian Belief Networks (BBN) apply Bayes’ Theorem to develop powerful, readily 
understood decision models. Some of the earliest clinical decision support systems were built 
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using BBN; recent examples include the application of BNN for providing diagnoses in liver and 
cardiovascular disease, in the evaluation of electroencephalograms in the intensive care unit, and 
in establishing prognosis for patients with head injuries [61, 67, 96]. 
BBN are acyclic directed graphs that paint both a quantitative and qualitative illustration of 
interactions among a set of variables [97]. In BBN, nodes (ovals) represent random variables and 
arcs (arrows) represent the direct probabilistic dependencies among the variables. When nodes 
are connected with arcs, the properties of the nodes become dependent upon each other, and a 
joint probability distribution is formed.  
In this study, SMILE, an inference engine, and GeNIe 2.0, a development environment for 
building graphical decision-theoretic models, were used to create the BBN [98]. Both 
applications were developed at the Decision Systems Laboratory at the University of Pittsburgh 
by Marek Druzdzel and his colleagues.  
In order to clearly demonstrate the structure and development of a BBN, a simple example 
illustrating the relationship between White Blood Cell (WBC) Count and Infection is shown in 
Figures 14-18 below. There are two nodes in this example: WBC Count and Infection. At least 
two states must exist for each node. In this case, WBC Count has three states: high, normal and 
low; and Infection has two: present and absent. The joint probability distribution is, as defined by 
the direction of the arc, the probability of each state according to the node upon which it is 
dependent. In this case, WBC Count is dependent upon Infection, meaning that the states for the 
WBC Count node must be defined for both states of the Infection node. The nodes and a 
hypothetical joint probability distribution are shown in Figure 14. 
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Figure 14: Bayesian Belief Network example- defining nodes, states and probabilities 
 
 
By setting the evidence for WBC Count to high, infection can be predicted. As shown in Figures 
15 and 16, if WBC Count is high, there is a 96% chance that Infection is present. The model can 
also be used in the reverse order, such that the presence of absence of Infection predicts the 
WBC count, as shown in Figures 17 and 18.   
 
 
 
 
 
 
Figure 15: Bayesian Belief Network example- setting WBC Count evidence 
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Figure 16: Bayesian Belief Network example- predicted Infection 
 
 
 
 
 
 
 
Figure 17: Bayesian Belief Network example- setting Infection evidence 
 
 
 
 
 
 
Figure 18: Bayesian Belief Network example- predicted WBC Count 
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In this study, the first step in creating the BBN was to define the nodes and their states. The 
nodes were those variables that were acquired through the expert interviews and data mining. For 
example, for the data category of patient demographics, the variables were primary device, days 
implanted, age, race, sex and diagnosis. Nodes were created to represent each of these variables 
and variable states were defined (e.g., for example, the states for sex were male and female). The 
second step was to define the direction of the arcs and the numerical parameters for filling in the 
joint probability distribution tables. All nodes were defined as having a direct relationship with 
patient outcome, and two states were defined for patient outcome: weaned and transplanted. 
Therefore, each variable state was defined for both weaned and transplanted patients, as shown 
in Table 5.    
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Table 5: Variable list with probabilities assigned for each state and outcome 
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4.3 MODEL INTERFACE DESIGN 
 
 
Anticipating clinical translation, a user-friendly graphical interface to the decision model was 
designed for a Pocket PC. A prototype was developed using Visual C++ 4.0 programming and 
SMILE for the Pocket PC 2003. 
 
 
4.3.1 Hardware  
 
 
With the clinical user in mind, a graphical user interface (GUI) was designed for a portable, 
hand-held computer known as a Pocket PC. As clinicians are often “on the go,” Pocket PC 
applications can be useful and readily implemented in a clinical setting. Several commercial 
Pocket PC applications exist and are currently used by clinicians for various functions including 
medical record entry and quick reference [99, 100]. Since 2002, the cardiovascular surgery unit 
at Miami Children’s Hospital has successfully used a fleet of Pocket PCs to gather patient 
information and write prescriptions [101]. 
A rechargeable Toshiba Pocket-PC model e355 with 3.5” TFT color display, 64MB RAM, 
and 300 MHz Intel PXA255 processor was used. This Pocket-PC was synchronized to an IBM 
ThinkPad model T40 notebook computer via the USB port. Minimum computer system 
requirements for synchronization were a 233MHz processor, 128 MB memory, and 65MB 
available hard disk space. 
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 4.3.2 Software 
 
 
Both the Pocket-PC and notebook computer used in designing the GUI were running the most 
up-to-date Microsoft operating systems (Pocket PC 2003 and Windows XP SP2). The code for 
the GUI was written using eMbedded Visual C++ 4.0 and SMILE for the Pocket-PC 2003 [98, 
102]. SMILE for the Pocket PC is a C++ library that performs decision analysis inference, it 
essentially allows the decision model that was created for the desktop computer to be fully 
implemented on the Pocket PC. To test the implementation, an emulated Pocket-PC, available as 
part of the Microsoft Software Development Kit for Pocket-PC 2003, was used [103]. 
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5.0 RESULTS 
 
 
 
As described in the methods section of this thesis, the structure and numerical parameters for the 
decision models were elicited from experts and/or learned from the patient data. Following the 
construction of Bayesian belief networks, each decision model was evaluated retrospectively. 
Models were evaluated based upon the accuracy with which they predicted the actual outcomes 
in the 19 patient cases considered for this study.  
The following three sections describe the results from each of the models (expert model, data 
model and hybrid model). Results will be reported in terms of the model’s ability to predict a 
True Wean (TW), a True Transplant (TT), a False Wean (FW) and a False Transplant (FT). A 
“true” scenario is one in which the model’s prediction matches the actual patient outcome and a 
“false” scenario is one in which the model predicts a different outcome. To further clarify, a TW 
occurs when the model predicts a wean and the real patient outcome indicates that the patient 
was weaned, while a TT occurs when the system predicts a transplant and the real patient 
outcome indicates that the patient was transplanted. A FW occurs when the system predicts a 
wean however the real patient outcome indicates that the patient was transplanted, while a FT 
occurs when the system predicts a transplant however the real patient outcome indicates that the 
patient was weaned. 
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5.1 EXPERT MODEL 
 
 
5.1.1 Decision Structure and Numerical Parameters 
 
 
5.1.1.1 Interview Results.     A decision flowchart describing the criteria used to identify 
VAD weaning candidates was compiled as a result of the expert interviews. The final decision 
flowchart is shown in Figure 19. The experts described a 5-tier health status screening followed 
by a 3-tier evaluation of cardiac recovery. They described an optimal weaning candidate as a 
non-ischemic patient who had been supported by the VAD greater than 4 weeks, had normal 
cardiac rhythm, positive nutritional status, and normal end organ function. Indices of cardiac 
recovery, as gathered through echocardiographic (ECHO) measurements, were considered 
optimal if the patient was able to maintain (with the VAD off) an ejection fraction (EF) of 
greater than 40%, ventricular power (PWR) greater than 4, and positive stroke area change (SA). 
Exercise study results were considered optimal if the patient was able to reach a peak oxygen 
consumption (MV02) of greater than 15 and maintain a respiratory exchange ratio (RER) greater 
than 1 when exercising with increased workload.  Right heart catheterization (RH CATH) results 
were considered optimal if the patient demonstrated a pulmonary capillary wedge pressure 
(PCWP) of less than 20, a cardiac index (CI) of greater than 2.2, and a heart rate (HR) of less 
than 100. As an alternative, experts reported that cardiac recovery could also be considered 
sufficient if at least 3 out of the following 4 indices were in the optimal range: EF, PWR, SA, 
and MVO2. 
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Figure 19: Final expert decision flowchart 
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5.1.1.2 Questionnaire Results.     As a result of the expert questionnaires, an 8x6 matrix of 
probabilities describing expert risk attitudes and treatment preferences was compiled. Shown in 
Figure 20 is a sample question and a portion of the output matrix; the questionnaire in its entirety 
is included in Appendix D.  In this example, the expert was asked if they would consider 
weaning a patient if the patient’s health status was inadequate but cardiac recovery was adequate. 
In accordance with the decision flowchart, the expert said no. However, when asked to estimate 
the percentage of patients who could be successfully weaned if 1 out 5 health status parameters 
were adequate, the expert answered 10% and 2 out 5 health status parameters adequate, 40%. 
The matrix of probabilities was entered in the outcome node of the BBN, as described in the next 
section. 
 
 
 
 
 
 
 
Figure 20: Sample question and probability matrix from expert questionnaire 
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5.1.2 Bayesian Belief Network Representation 
 
 
The final expert decision model in BBN form is shown in Figure 21. This model is similar in 
structure to the decision flowchart in that two groups of nodes exist, those that describe the 
patient’s health status and those that describe the patient’s cardiac recovery (the states for each of 
the nodes are already shown in Figure 19, and as such will not be repeated here). The main 
difference between the BBN and the decision flowchart is the addition of the Outcome node, 
shown here in the center of the network. The outcome node contains the 8x6 matrix of 
probabilities given through the expert questionnaire. Specifically, this node contains a 
probability for the two states of Outcome (Wean, Transplant) for each of the 6 states of the 
Health Status node (all adequate, all inadequate, 1/5 adequate, 2/5 adequate, 3/5 adequate, 4/5 
adequate) and each of the 8 states of the Cardiac Recovery node (all adequate, all inadequate, 
only echo adequate, only exercise adequate, only rh cath adequate, echo and exercise adequate, 
echo and rh cath adequate, and exercise and rh cath adequate). 
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Figure 21: Final expert decision model  
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5.1.3 Evaluation 
 
 
The predictive accuracy of the expert decision flowchart, shown in Figure 19, is given in Table 
6. The predictive accuracy of the final expert decision model, shown in Figure 21, is shown in 
Table 7.   
 
 
 
Table 6: Predictive value of expert decision flowchart 
 
 
True Wean True Transplant False Wean False Transplant 
1 9 0 9 
 
 
 
 
Table 7: Predictive value of expert decision model 
 
 
True Wean True Transplant False Wean False Transplant 
6 9 0 4 
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5.2 DATA MODEL 
 
 
5.2.1 Decision Structure and Numerical Parameters 
 
 
In acquiring the knowledge from the data, 7 categories of data, 250 variables and 10 pages of 
text per patient were analyzed for each of the 19 patients, each with an average of 124 days 
worth of data. 
 
 
5.2.1.1 Artificial Neural Network Results.     The ANN were used to analyze the numerical 
data from the demographics, complications, labs, rh cath, echo, and exercise categories. The 
analysis resulted in an 89% reduction in the data set-- 28 of the 250 variables were found to 
correlate closely with outcome. These 28 variables are shown below, in Tables 8-13, organized 
by data category. The states for each of these variables, for each of the two patient outcomes are 
also shown.  
In terms of Patient Demographics, the ANN analysis describes an ideal candidate for 
weaning as one who was supported by an LVAD rather than a BiVAD, implanted for less than 
100 days, less than 38 years old, Caucasian, female, and non-ischemic (Table 8).  
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Table 8: Minimized set of Patient Demographics variables 
 
 
 
 
 
 
 
As noted in the analysis of the Complications variables (Table 9), an ideal candidate for weaning 
is one with no history of renal complications or tamponade. In addition, the results indicate that 
candidates are more likely to be transplanted if they have a history of reoperation or 
complications associated with bleeding.  
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Table 9: Minimized set of Complications variables 
 
 
 
 
 
 
In terms of Laboratory Tests (Table 10), the ANN analysis associated a greater chance of 
weaning with patients who had normal laboratory values for Aspartate Amino Transferase 
(AST), Urea Nitrogen (UREAN), Reticulocyte Count (RET), Lactic Dehydrogenase (LD), 
Magnesium (MG) and Creatinine Clearance (CREAT).   
 
 
 
 55
Table 10: Minimized set of Laboratory Test variables 
 
 
 
 
 
 
Indices of cardiac recovery, as described by the ANN analysis included measures derived from 
the exercise study, rh cath study and echo study. For the exercise test variables (Table 11), 
optimal candidates include those who are able to exercise for longer than 5 minutes, have greater 
than 45% of predicted peak exercise oxygen consumption (V02%), have metabolic equivalents 
greater than 4 (METS), and can perform at greater than 80% of maximum predicted heart rate 
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(HR% Target). Optimal RH Cath variables include (Table 12) a pulmonary capillary wedge 
pressure of less than 24 (PCWP), pulmonary vascular resistance of less than 1.1 (PVR), mean 
pulmonary artery pressure of less than 25 (mPap), and a transpulmonary gradient of less than 10 
(TPG). Finally, the optimal echocardiographic measurements (with VAD off or at half support) 
include ventricular power of greater than 4 (PWR), a positive increase in stroke area (SA), stable 
systolic arterial pressure (ApSys), and stable fractional area change (FAC) (Table 13).     
 
 
 
Table 11: Minimized set of Exercise Test variables 
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Table 12: Minimized set of RH Catheterization variables 
 
 
 
 
 
 
Table 13: Minimized set of Echocardiographic variables 
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5.2.1.2 Natural Language Processing Results.     NLP was used to analyze the free text in 
the patient shift notes. Five contextual categories were formed as a result of the NLP: VAD 
malfunction, socialization, ambulation, positive descriptors, and nutrition. These categories, as 
well as an example of the words that fall underneath each, is detailed in an excerpt of raw data 
included in Appendix E. When compared to transplanted patients, weaned patients exhibit fewer 
reports of VAD malfunction, better nutritional status, greater activity level, can be described in 
more positive ways, and receive more visits from family and friends, as shown in Figure 22.  
 
 
 
 
 
 
Figure 22: Natural language processing results for of shift notes 
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5.2.2 Bayesian Belief Network Representation 
 
 
The final data decision model in BBN form is shown in Figure 23 below. For the sake of clarity, 
the 7 categories of data are color coded and variables belonging to each category are clustered 
together.  
 
 
 
 
 
 
Figure 23: Final data decision model  
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5.2.3 Evaluation 
 
 
The predictive accuracy of the final data decision model, shown in Figure 23, is shown in Table 
14.   
 
 
 
Table 14: Predictive value of data decision model 
 
 
True Wean True Transplant False Wean False Transplant 
9 8 1 1 
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5.3 HYBRID MODEL 
 
 
5.3.1 Decision Structure and Numerical Parameters 
 
 
The structure and numerical parameters for the hybrid model were inherited directly from the 
expert and data models, shown in Figures 21 and 23.   
 
 
5.3.2 Bayesian Belief Network Representation 
 
 
The final hybrid decision model in BBN form is shown in Figure 24 below. This model was 
formed through a direct combination of the final expert and data models. As the variables and 
their states have been described in previous sections of this thesis, they will not be repeated here. 
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Figure 24: Final hybrid decision model 
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5.3.3 Evaluation 
 
 
The predictive accuracy of the final hybrid decision model, shown in Figure 24, is shown in 
Table 15.   
 
 
 
Table 15: Predictive value of hybrid decision model 
 
True Wean True Transplant False Wean False Transplant 
9 9 0 1 
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5.4 MODEL INTERFACE 
 
 
5.4.1 Expert model interface 
 
 
5.4.1.1 Design Features.     The Pocket PC model interface was designed to facilitate data 
entry and display the decision model results to the clinician in a user-friendly, uncomplicated 
format. When the program is started, a file management screen is presented to the user, as shown 
in Figure 25. This screen allows the user to choose whether they want to update, delete or add a 
patient file. The update and add functions allow access to the data entry and decision support 
levels of interface, shown in Figures 26 and 27. Due to the limited area to display information on 
the Pocket PC screen, the data entry level utilizes a series of tabbed panels. Also, in order to 
standardize the format in which data is entered, each data input field utilizes a pre-formatted drop 
down list. The user simply chooses a value for each field from this list and moves from tab to tab 
until all data is entered for the patient. Finally, on the decision support tab, the user is presented 
with a probability (percentage) that describes whether or not this patient can be successfully 
weaned, as well as a list of recommendations for improving their chances of recovery, as shown 
in Figure 27; these recommendations are simply a list of variables that are not in their optimal 
states for that particular patient. 
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5.4.1.2 Prototype Images 
 
 
 
 
 
 
Figure 25: File management screen of user interface 
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Figure 26: Data entry tab of model user interface 
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Figure 27: Decision support tab of model user interface 
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6.0 DISCUSSION AND CONCLUSIONS 
 
 
 
6.1  EXPERT MODEL 
 
 
Of the 19 patients included in this study, the expert model was able to correctly predict 100% of 
the transplants and 60% of the weans. The expert model appears to be a rather conservative 
approach to identifying candidates for VAD weaning, given the number of false transplants it 
predicted.  
The results of this model demonstrate that experts did not follow the rational approach that 
they defined in their interviews. The fact that this model, which was based solely on expert input, 
was not able to correctly predict the same cases that the experts themselves did can mean a 
number of things. It is possible that the knowledge acquisition techniques used to elicit 
information from the experts were not rigorous enough, leaving critical information out of the 
final decision flowchart. Furthermore, the interviews also have their limitations-- they do not 
reflect the disagreements and hierarchical conflicts that occur in group decisions. It is also 
possible that the experts themselves left out important input when they asked to edit the 
combined flowcharts.  By comparing the predictive accuracy of the decision flowchart to the 
predictive accuracy of the BBN, it is clear that preferences and risk attitudes do play a large role 
in the decision making process for experts—for example, many clinicians will consider weaning 
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even if health status is technically inadequate. It is quite possible that clinicians are less 
conservative and algorithmic in real life than was described through these questionnaires.  
 
 
 
6.2  DATA MODEL 
 
 
The data model was able to correctly predict 90% of the transplants and 90% of the weans.  
However, this model also predicted a wean for a patient who was actually transplanted. As this is 
considered a dangerous scenario in clinical prediction, the data model can be considered a 
relatively aggressive approach to identifying candidates for VAD weaning.  
The results of this model show that patterns in the patient data are significant and include 
variables that are not formally included in the experts’ assessments of cardiac recovery. While 
none of the patterns in the data were particularly groundbreaking or surprising (and in fact 
correlated with many of the results in published studies), the idea of including these data in the 
decision making process addresses the problem of selector bias in clinical experience with VAD 
weaning. It is evident that clinicians choose to formally screen “healthier” patients who “exhibit 
signs of being recoverable;” however, a method for quantifying these signs is not yet in place. 
The data model gestures toward the importance of including these types of variables and toward 
a way of quantifying these signs. This would be the significant step in developing a standardized 
protocol for selecting patients to screen for recovery (so that clinical experience at one center can 
be compared to the clinical experience at another).   
Although the results of this model are highly encouraging, there are two noteworthy 
limitations that must be considered before drawing large conclusions. The first limitation is 
associated with the sample size used in this study.  When training data, typically, one takes only 
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half of the data to train with and uses the other half for evaluating the predictability of the model. 
While this would be an ideal course of action, because our data set was so small, the entire set 
had to be used; the subjects that were used to test the model were the same subjects that were 
used to train it. While SPSS Clementine uses a 50% method to minimize the risk of overtraining 
of the data, training and evaluating using the same data set is not ideal. The second limitation is 
the quality of the data. Although the data is being analyzed in an objective manner, the data itself 
is by no means objective.  It needs to realized that there is a there is a layer of decision making 
that is already part of the data before it is ever entered into the decision model.  To clarify 
through an example, all VAD patients suffer through bleeding problems. However, in some 
cases, the data indicates a complication due to bleeding and in other cases, the patient is not 
listed as having any such complications. The decision of whether bleeding is actually a 
complication is often interpreted differently by different clinicians and as such could be entered 
into the database already biased.  
In addition to these limitations, there is a major assumption that was made when constructing 
this model: it was assumed that the clinician’s final decision to wean or transplant the patient was 
correct. However, how can we ultimately know that clinician made the right choice for the 
patient? While we can look at the follow-up data to see if the weaned patients maintained their 
recovery, it is very important to realize that the model itself is based upon the fact that the 
decisions made by the clinicians were correct.  
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6.3  HYBRID MODEL 
 
 
The hybrid model correctly predicted 100% of the transplants and 90% of the weans. Out of 19 
cases, the model incorrectly predicted one patient case. In this case, the model predicted a 
transplant where the patient was actually weaned. Interestingly, it should be noted that follow-up 
data for the patient indicated that 1 year post-explant, ventricular failure occurred and the patient 
required a transplant. Due to the high predictive accuracy, in this study, the hybrid model is 
considered the best overall approach to identifying VAD weaning candidates. 
This model has shown that if expert- and data-derived knowledge are combined into one 
model, it is possible to predict patient outcome with greater accuracy than by using each source 
of knowledge separately. This may be because the combined models appear to compensate for 
their limitations. For example, the data model may be adding information where the expert 
model lacked insight and the expert model may be adding some conservativism where the data 
model is too relaxed. 
The predictive accuracy of this model indicates that a hybrid system has the potential to 
augment and support, as a decision support system should, the clinicians’ decision making 
process when identifying VAD weaning candidates. Also, it represents a feasible method for 
sharing expert- and data-derived knowledge among other centers with varying degrees of 
experience.  
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6.4  MODEL INTERFACE 
 
 
The model was able to be fully implemented on a Pocket PC. The interface is user-friendly and 
due to its portability, it is a convenient choice for clinicians. A pilot study would reveal areas for 
improvement and expansion, however, the infrastructure of the interface, as designed for this 
study, is flexible enough to incorporate these changes as they arise. 
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7.0 STUDY SIGNIFICANCE 
 
 
 
This study has proven the feasibility of developing a DSS for identifying and evaluating VAD 
weaning candidates. While the study has its limitations, the results are encouraging and certainly 
warrant further investigation.  
It is hoped that this study has made a step towards showing that the use of a DSS in this 
patient population has the potential to promote responsible and wide-spread use of VADs for 
cardiac rehabilitation, not only for the patients that are being treated with VADs as a BTT, but 
also for the thousands of heart failure patients who could potentially benefit from VAD therapy 
for the specific purpose of BTR.  
Furthermore, this study represents the first efforts in applying a DSS in VAD patient care. As 
complex decisions surround many aspects of the care of VAD patients, this study can hopefully 
encourage and provide a framework for future development of DSS in this patient population.  
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8.0 FUTURE DIRECTIONS 
 
 
 
Due to the promising results of this study, it is recommended that further development of this 
model continue. First, in order to strengthen the expert model, more knowledge should be 
acquired from the experts. However, a more rigorous technique should be employed; several 
computer-aided knowledge elicitation techniques exist and are available commercially for this 
purpose. Second, a local expansion of the data-derived knowledge base is recommended. This 
could include formal measures of quality of life, functional assessments, and temporal analysis 
of hemodynamic data. Thirdly, a prospective multi-center expansion of both the expert- and 
data-derived knowledge base is recommended. Not only would it be interesting to test the 
predictive accuracy of these models on a separate data set, but with this larger sample size, it 
would be possible to constructively respond to the main critique of this study—that the model 
was evaluated using the same data on which it was built. Fortunately, with the advent of the 
International Society of Heart and Lung Transplant VAD registry, a larger set of weaning data 
will soon be available for analysis. With a larger number of patient cases, the model can be built 
using half of the data set and tested on the other, thereby decreasing the chance of overtraining 
the Artificial Neural Networks and increasing the acceptance of the decision structures.  
 75
 
 
 
 
 
APPENDIX A 
 
 
 
EXPERT PANEL AND AREAS OF EXPERTISE 
  
 
 
Robert Kormos, MD: Cardiothoracic Surgeon, Director AHP, UMPC 
 Implant/weaning/explant of LVADs 
 Heart Transplant 
 LVAD patient treatment: from admission to discharge 
 
Michael Mathier, MD: Cardiologist, UPMC 
John Gorscan, MD: Cardiologist, UPMC 
 Echocardiography 
 Heart Failure 
 LVAD Patient Selection 
 
Eileen Stanford, RN: Clinical Nurse Coordinator AHP, UPMC 
Lisa Carozza, RN:  Nurse Supervisor AHP, UPMC 
 Clinical interaction with patients 
 Nutrition 
 Exercise 
 Infection Management 
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 Pharmacology 
 Patient Education/Consent 
 
Margo Holm, PhD: Occupational Therapist, UPMC 
Ketki Desai: Occupational Therapist, UPMC 
 Functional Assessment of LVAD patients 
 Cognitive Asessment  
 Physical Assessment 
 
Mary Amanda Dew, PhD: Psychiatry, UPMC 
 Quality of Life of LVAD patients 
 
Steve Winowich, PhD: Director of Clinical Engineering AHP, UPMC 
Rick Schaub, PhD: Clinical Engineer AHP, UPMC 
Don Severyn: Clinical Engineer AHP, UPMC 
 Echocardiography 
 Exercise Study 
 Clinical Application and Maintenance of LVADs 
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APPENDIX B 
 
 
 
NUMERICAL DATA CATEGORIES AND VARIABLES 
 
 
 
Table 16: Patient Demographics Variables 
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Table 17: Laboratory Test Variables 
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Table 18: Right Heart Catheterization Variables 
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Table 19: Echocardiographic Variables 
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Table 20: Exercise Test Variables 
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Table 21: Complications Variables 
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APPENDIX C 
 
 
 
EXCERPT FROM A SHIFT NOTES FILE 
 
 
 
Patient ID: 9264 
Outcome: Weaned 
 
PO 3.5 initially but quickly poor flows -tried ECMO to  Left Atrium but lots of air in  ECMO 
circuit   
Back on CPB Then LVAD only @1:09am  PO 4.3.-4.7  VOL; ET = 300MS ;DP=200;VAC=-
8;+FILL ;+EMPTY  
Dr Kormos wants low vac allow Lv  to do some work and not  
 PO:5.2-5.3; PR: 80-89, VOL, ET 290ms; DP: 202-204; Vac: -4 to -10 +flash 
MAP 80-90, CVP 11-18.  IVAD had a few vacuum alarms early in the shift, going to +4.  Vac 
was dialed slightly more negative, as we were told to keep it under  -10.  No other alarms d  
 PO 4.5 through most of day.  wking up in mid-morning.  possibility to extubate this evening.  
IVAD flash functioning properly.  vaccuum still kept low at Dr. Kormos' request. 
  
 LVAD: PO 5.0 PR 77 %sys 38,290 DP 202 V -10 
MAP 86 PAP 27 HR 94 CVP 17 
flash working properly.  
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PO 5.2-5.7 lpm in volume. Good flash on black box. Patient seeming to have difficluties in being 
responsive 
Pt is still intubated in the ICU..  Flows were 5.0-6.1 Left with good ejection on the black box.  
CVP: 11-18.. 
 PO:5.2-6.1, PR:80-95, %sys:39-46, Et 290, Prs:218-220, Vac:-12 -14 
No events 
  
 PO:4.8-5.9, PR:76-93, ET 300ms, DP 224-228, Vac: -5 to -16 +flash 
Patient was extubated this morning and seems to be coherent.  Nurse got him out of bed and he 
sat in the chair from 4pm on.  Flows dropped when he first sat up, but quickly rebounded.  Ever  
 LVAD: PO 5.0-6.1 PR 80-84 %sys 40, 300 DP 226 V -6,-14 
CVP 9; HR 94 MAP 85  
 PO 5.3-5.7, PR 82-87, ET 300ms, DP 224-225, Vac -10 to-14 +flash 
Patient was sitting in the chair at beginning of the shift.  He was complaining about abdominal 
discomfort and nurse thinks it may be pump related.  
  
PO: 5.3-4.8  PR: 83-75  ED: 300   good flash  stable BPs 
 LVAD: PO=5.3-5.5 LPM; PR=83-86 BPM; VOL; ET=300 ms; DP=223-225 mmHg; VP= -10 
to -16 mmHg; + Flashes 
No alarms.  Patient was awake and sitting upright in a chair during the early evening before 
being laid down again and sleeping for the duration of the nig  
 5.1-5.3 Vol 79-82 
+ flash 
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sleeping - sitting in chair this morning  
 MAP 64-65; CVP 6-8; HR 88-104 bpm 
po 5.3-5.7 l/min; pr 82-87 bpm; 37-44%; 300 ms; + flash 
In bed.  Had visitors/asleep.  
LVAD 5.0-5.4, DP ~ 225 mmHg, vac ~ -15 mmHg, MAP ~ 65 mmHg, consistent eject flash, 
was to go to 7F but no available beds, will go in am 
 MAP 61-86; CVP 13-16; HR 93-102 bpm 
po 5.4-6.2 l/min; pr 84-96 bpm; 42-48%; 300 ms; + flash 
In bed, asleep.  Awake in morning watching tv.    
 
LVAD: 5.2-6.2, good eject flash, MAP ~ 68-89 mmHg, pt. sat in chair from 11:30 am on.  Pt. 
will stay in icu because of hypotension last night and becuase he was febrile. 
 5.5-6.1 Vol 86-95 
+ flash 
sleeping 
getting swan this morning, hopefully moving upstairs today  
 MAP 66-79; HR 92-97 bpm 
po 5.3-6.1 l/min; pr 82-95 bpm; 41-47%; 300 ms; + flash 
In chair/in bed.  
Hemodynamically stable.  Outputs about 5.5 liters per min, and a consistent empty signal.  Some 
concern over WBC and Temp.; Swaned late in afternoon - cardiac output > 11 lit/min causing 
some concern over possible sepsis.  Also have a TTE scheduled for to 
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 PO 5.7-5.9; PR 89-91; vol; %sys 44-45; ET 300ms; DP 223-224; Vac -15 to -14; +Empty Signal 
In bed/sleeping all shift.  
  
 HR 91-96 bpm; MAP 62-79 
po 5.9 l/min; pr 80-92 bpm; 41-46%; 300 ms; + flash 
In chair.  
 5.6-5.9 vOL 87-92 
+ FLASH 
sleeping 
nurse said pt going for wean test today  
 PO: 5.7-5.9 PR: 89-92 VOL (299msec) max:223 min:-15/-20 
good flash  
 LVAD 5.6-.6.0 VOL + FLASH 
moved up to 7F yesterday 
worked with PT Stood -a lttle light headed and VERY nauseas sat down  
after a little bit felt better stood walked 4 steps and back to bed 
became orthostatic as flows dropped and had asynch alarm 
prevouisl  
 LVAD: PO 5.3-6.1 PR 82-93 VOL ED 299 DP 221/226 V -13/-18 
+ Flash...got paged because of sync alarms...pt was using the bathroom and flows were 
4.2...nurses got patient into bed and flows returned to previous values...  
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APPENDIX D 
 
 
 
EXPERT QUESTIONNAIRE 
 
 
 
A. Would you wean if the patient’s health status and cardiac recovery are adequate? 
Yes  No 
Percent of patients who would likely be successfully weaned if: 
100       90     80   70 60 50 40 30 20 10 0  
Percent of patients who would likely be unsuccessful weaned if: 
100       90     80   70 60 50 40 30 20 10 0  
 
B. Would you wean if the patient’s health status and cardiac recovery are inadequate? 
Yes No 
 
Percent of patients who would likely be successfully weaned if: 
 
1 out of 5 health status parameters inadequate and 
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
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1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0  
 
2 out of 5 health status parameters inadequate and 
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0  
 
3 out of 5 health parameters inadequate and 
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
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100       90     80   70 60 50 40 30 20 10 0  
 
4 out of 5 health parameters inadequate and  
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0  
 
5 out of 5 health parameters inadequate and 
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0  
 
 Percent of patients who would likely be unsuccessful weaned if: 
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1 out of 5 health status parameters inadequate and 
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0  
  
2 out of 5 health status parameters inadequate and 
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0  
 
3 out of 5 health parameters inadequate and 
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
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1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0  
 
 4 out of 5 health parameters inadequate and  
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0  
 
 5 out of 5 health parameters inadequate and 
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
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100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0   
  
C. Would you wean if the patient’s health status is inadequate but cardiac recovery is 
adequate? 
Yes No 
 
Percent of patients who would likely be successfully weaned if: 
 
1 out of 5 health status parameters inadequate 
100       90     80   70 60 50 40 30 20 10 0  
2 out of 5 health status parameters inadequate 
100       90     80   70 60 50 40 30 20 10 0  
3 out of 5 health status parameters inadequate  
100       90     80   70 60 50 40 30 20 10 0  
4 out of 5 health status parameters inadequate 
100       90     80   70 60 50 40 30 20 10 0  
5 out of 5 health status parameters inadequate 
100       90     80   70 60 50 40 30 20 10 0  
  
Percent of patients who would likely be unsuccessfully weaned if: 
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1 out of 5 health status parameters inadequate 
100       90     80   70 60 50 40 30 20 10 0  
2 out of 5 health status parameters inadequate 
100       90     80   70 60 50 40 30 20 10 0  
3 out of 5 health status parameters inadequate  
100       90     80   70 60 50 40 30 20 10 0  
4 out of 5 health status parameters inadequate 
100       90     80   70 60 50 40 30 20 10 0  
5 out of 5 health status parameters inadequate 
100       90     80   70 60 50 40 30 20 10 0  
 
 D. Would you wean if the patient’s health status is adequate but cardiac recovery is 
inadequate? 
Yes  No 
 
Percent of patients who would likely be successfully weaned if: 
 
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
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RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0 
 
Percent of patients who would likely be unsuccessfully weaned if: 
 
2 out of 2 weaning trials adequate but RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath adequate 
100       90     80   70 60 50 40 30 20 10 0  
1 out of 2 weaning trials adequate and RH Cath inadequate 
100       90     80   70 60 50 40 30 20 10 0  
RH Cath adequate but no weaning trials adequate 
100       90     80   70 60 50 40 30 20 10 0 
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APPENDIX E 
 
 
 
EXCERPT OF NATURAL LANGUAGE PROCESSING DATA 
 
 
 
Table 22: Natural Language Processing Frequency and Category Assignment 
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